| Description | PMEDAP is a potent inhibitor of Moloney murine sarcoma virus (MSV)-induced tumor formation and associated mortality and an inhibitor of human immunodeficiency virus (HIV) replication. PMEDAP also has anti-murine cytomegalovirus (MCMV) activity. |
| In vivo | 在三周龄的雄性NMRI小鼠中，接种MSV后，PMEDAP（0.25-5 mg/kg；IP；每日）显著延迟了肿瘤出现时间，并提高了携肿瘤小鼠的存活率。PMEDAP亦以剂量依赖的方式抑制了肿瘤形成和死亡率[2]。 |
| molecular weight | 288.2 |
| Molecular formula | C8H13N6O4P |
| CAS | 113852-41-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | 0.1 M NaOH: 14.29 mg/mL (49.58 mM), when pH is adjusted to 12 with NaOH. Sonication is recommended. |
| References | 1. Naesens L, et al. 9-(2-Phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP): a novel agent with anti-human immunodeficiency virus activity in vitro and potent anti-Moloney murine sarcoma virus activity in vivo. Eur J Clin Microbiol Infect Dis. 1989;8(12):1043-1047. 2. Neyts J, et al. Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo [published correction appears in Eur J Clin Microbiol Infect Dis 1993 Jul;12(7):following 477]. Eur J Clin Microbiol Infect Dis. 1993;12(6):437-446. |